A phase Ib/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago Phase II Consortium study. KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma. Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel V.T. Henderson L, Xu P, ODay E, Cecchi F, Blackler A, Liao WL, Hembrough T, Catenacci DVT, Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer, Daniel V.T. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Dr. Catenacci is of the University of Chicago Medical Center and Biological Sciences. Both bring a successful background in biotech and not only discuss . Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. Catenacci, Tanguy Y. Seiwert. JS Ross, K Wang, DVT Catenacci, J Chmielecki, SM. Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations. Catenacci, Joseph Chao, Kei Muro, Salah-Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem. Julie Iromuanya. If this issue persists, please contact the University of Chicago Medicine. Search below to find a doctor with that skillset. Catenacci, Gustavo M. Cervantes, Soheil Yala, Erik A. Nelson, Essam El-Hashani, Rajani Kanteti, Mohamed El Dinali, Rifat Hasina, Johannes Brgelmann, Tanguy Y. Seiwert, Michele Sanicola, Les Henderson, Tatyana A. Grushko, Olufunmilayo I. Olopade, Theodore Karrison, Yung-Jue Bang, Woo Ho Kim, Maria Tretiakova, Everett E. Vokes, David A. Frank, Hedy L. Kindler, Heather Huet, Ravi Salgia, Daniel V.T. Looking for something else? Dr. Daniel Vt Catenacci, MD, is a Hematology/Oncology specialist in Chicago, Illinois. March 1st 2018. A subgroup cluster-based Bayesian adaptive design for precision medicine. Catenacci DVT, Xu P, Henderson L, Liao WL, Burrows J, Hembrough T. Development of a quantitative colorectal cancer SRM assay for use in FFPE tumor tissues. Catenacci, Joseph Chao, Marwan Fakih, Samuel J. Klempner, Jeffrey S. Ross, Garrett M. Frampton, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock. Dr. Catenacci frequently treats Pancreatic Neoplasms and Gastrointestinal Neoplasms. The charge is punishable by up to 20 years in federal prison. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). Tumor genome analysis includes germline genome: Are we ready for surprises? UC San Diego Health 200 W Arbor Dr San Diego, CA 92103. . Accepting new patients. Daniel V.T. For help with MyChart, call us at 1-844-442-4278. New patients are welcome. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Dr. Schell is board certified in Obstetrics and Gynecology, with a sub . Robert de Wilton Marsh, Mark S. Talamonti, Marshall S. Baker, Mitchell C. Posner, Kevin K. Roggin, Jeffrey B. Matthews, Daniel V.T. Wentian Guo, Yuan Ji, Daniel V.T. Catenacci. Catenacci, Carlos H. F. Chan, David B. Chapel, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Ricardo R. Lastra, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, John Moroney, Aytekin Oto, Colette R. Pameijer, Sam G. Pappas, Patricio M. Polanco, Blase N. Polite, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Ghassan K. Abou-Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. A Contreras, R Purcell, DVT Catenacci, TK Hale, M Tretiakova, R Salgia, M Sullivan, J Hart. Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blase Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga, Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence, Koosha Paydary, Natalie Reizine, Daniel V.T. . Catenacci. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Medical Oncology Male Age 46. Oncologists diagnose and treat cancers of all types. Daniel Catenacci University of Chicago Medical Center 5841 S Maryland Ave Chicago, IL 60637 Specialty: Hematology & Oncology. Arraignment in federal court in Chicago has not yet been scheduled. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. and is affiliated with The University Of Chicago Medical Center. Home; . A spokesperson for the school said he is on a leave of absence. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. Daniel V.T. Make an Appointment (847) 662-1818. Career Development Seminar for Summer Research Students. A spokesman for the University of Chicago said Catenacci is on a leave of absence and not currently engaged in research or otherwise seeing patients. View hours, services and more. Catenacci, Blase N. Polite, Cara A. Rosenbaum, Azadeh Namakydoust, Theodore Karrison, Thomas F. Gajewski, Hedy L. Kindler, Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer, Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci, Salah-Eddin Al-Batran, James Posey. Daniel Catenacci, MD, Associate Professor of Medicine, is an adult GI medical oncologist, and Director of the gastrointestinal oncology program at the University of Chicago. Catenacci, M.D., director of the GI oncology program at the University of Chicago, settled charges with the U.S. Securities and Exchange Commission over insider trading. Advanced Fertility Center of Chicago. One of the world's leading research universities, the University of Chicago inspires scholars to pursue field-defining research, while providing a transformative education for students. RON SRM assay for use in formalin fixed tumor tissues. Get an online second opinion from one of our experts without having to leave your home. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneityPANGEA. Daniel V.T. This work was supported by a National Institutes of Health K12 award (CA139160-01A), University of Chicago Comprehensive Cancer Center Award in Precision Oncology, and LLK Foundation Award (Dr Catenacci). Catenacci, Minori Koshiji Rosales, Hyun Cheol Chung, Harry H. Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang, Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma, Yaniv Berger, Darryl Schuitevoerder, Charles C. Vining, Lindsay Alpert, Emily Fenton, Enal Hindi, Chih-Yi Liao, Ardaman Shergill, Daniel V.T. RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Communicate with your doctor, view test results, schedule appointments and more. Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam. Shankaran V, Muro K, Bang YJ, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Loboda A, Albright A, Cristescu R, Murphy E, McClanahan T, Ayers M, Nebozhyn M, Lunceford J, Koshiji M, Heath K, Cheng J, Chung HC. Sign up for our Newsletter Enter your email. Find other locations and directions. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity PANGEA. (Oral Presentation), K Muro, YJ Bang, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, R Berger, EJ Gonzalez, J Pulini, A Ray, M Dolled-Filhart, K Emancipator, K Kort, K Pathiraja, X Shu, M Koshiji, J Cheng, H C ChungA. In November 2020, Dr. Catenacci used material, non-public information about the trial results to make more than $134,000 in illegal profits from the purchase and sale of securities in the company, according to a criminal information filed Friday in U.S. District Court in Chicago. and West)--Challenging Cases (Session Chair). applebaumm@uchicago.edu. A safety and Feasibility trial. Dr. Samuel J. Klempner is an oncologist specializing in gastrointestinal cancers at Massachusetts General Hospital.. Dr. Eirini Pectasides is a medical oncologist at the Dana-Farber Cancer Institute specializing in gastrointestinal cancers.. Dr. Daniel V. T. Catenacci is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. Schrock, A. B.,Ouyang, C.,Sandhu, J.,Sokol, E.,Jin, D.,Ross, J. S.,Miller, V. A.,Lim, D.,Amanam, I.,Chao, J.,Catenacci, D.,Cho, M.,Braiteh, F.,Klempner, S. J.,Ali, S. M.,Fakih, M. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Gain a better understanding of fertility as we explore what happens during ovulation and how to get pregnant. Learn more about what frozen shoulder is, its symptoms and causes and how to get proper care for the condition. Daniel Catenacci's Tweets. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, John Hart, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Dejan Micic, Harveshp Mogal, Mecker G. Mller, Garrett M. Nash, Aytekin Oto, Colette R. Pameijer, Sandeep Parsad, Pritesh R. Patel, Blase N. Polite, Sam G. Pappas, Patricio M. Polanco, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Namrata Setia, Maheswari Senthil, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Brandy Strickland Snyder, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms, Claire Hoppenot, Darryl Schuitevoerder, Francisco J. Izquierdo, Alejandro Plana, Bhavana Pothuri, S. Diane Yamada, Josephine S. Kim, Nita K. Lee, Daniel E. Abbott, Sherif Abdel-Misih, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Wilbur B. Bowne, Charles Komen Brown, Daniel V.T. Catenacci, Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial, Daniel V.T. Challenges of applying tumor genome analysis to the germline: Examples from GI Oncology. Adjuvant Chemotherapy for Colon Cancer: Towards a Personalized Approach. Catenacci has held positions at the University of Chicago Medicine for over 15 years, starting as a fellow in Hematology and Medical Oncology from 2006 to 2010. Daniel M. Geynisman, Daniel V.T. Smita S. Joshi, Daniel V.T. Catenacci, Howard S. Hochster, James M. Ford, Pamela L. Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C. Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert C. Gagnon, Peter L. Bonate, Li Liu, Tona M. Gilmer, Donald P. Bottaro. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Targeted Therapies A New Generation of Cancer Treatments.. Washington D.C., Dec. 20, 2021 . Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. Schedule your appointment online for primary care and many specialties. E An; WL Liao; S Thyparambil; J Rodriguez; R Salgia; II Wistuba; J Burrows; T Hembrough; DVT Catenacci, Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue, Daniel V.T. RON upregulation is a resistance mechanism to MET directed therapy in MET driven Development of a clinical cMet SRM assay and assessment of assay precision in archival formalin fixed paraffin embedded (FFPE) sections. Gastrointestinal Cancer + 1 more subspecialties. Dr. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, University of Wisconsin - Madison . Catenacci, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study, Yung Jue Bang, Yoon-Koo Kang, Daniel V.T. By Daniel Catenacci, MD, University of Chicago Medicine. Following this, Dr Catenacci held positions at . Treatment of Advanced Gastroesophageal Cancer: A Focus on Targeted Therapies - JACOB phase III Clinical Trial Investigators Meeting: A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and Catenacci, Wei-Li Liao, Sheeno Thyparambil, Les Henderson, Peng Xu, Lei Zhao, Brittany Rambo, John Hart, Shu-Yuan Xiao, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, David B. Krizman, Fabiola Cecchi, Donald P. Bottaro, Theodore Karrison, Timothy D. Veenstra, Todd Hembrough, Jon Burrows, Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies, Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Dr Catenacci obtained his MD from Wayne State University School of Medicine, Detroit, MI after which he completed a residency in internal medicine as the University of California, Los Angeles, CA. The information charges Dr. Catenacci, 45, of Chicago, with one count of securities fraud. Invited Panelist for the Foundation One Virtual Tumor Board. Hospital affiliations include University Of Chicago Medicine. A pan-cancer organoid platform for precision medicine. Kinase activity profiling combined with genotyping as a tool for predictive biomarker discovery for the treatment of gastroesophageal Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. 3.3 (9 ratings) Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip A. Philip, Peter C. Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, Jordan M. Cloyd, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Vadim Gushchin, Carla Harmath, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Aytekin Oto, Colette R. Pameijer, Patricio M. Polanco, Sam G. Pappas, Blase N. Polite, Richard E. Royal, George I. Salti, Armando Sardi, Namrata Setia, Lucas Sideris, Joseph Skitzki, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, Paul H. Sugarbaker, Charles A. Staley, Daniel M. Labow, Jason M. Foster, Jesus Esquivel, H. Richard Alexander, Edward A. Levine, Laura A. Lambert, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations, Alejandro Plana, Francisco J. Izquierdo, Darryl Schuitevoerder, Laura A. Lambert, Dejan Micic, Jeremiah L. Deneve, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Wilbur B. Bowne, Charles Komen Brown, Andrea Hayes-Jordan, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg. Manish R. Sharma, Smita S. Joshi, Theodore Karrison, Kenisha Allen, Grace K. Suh, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Daniel V.T. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Catenacci, Kiran K. Turaga. Catenacci, Manfred B. Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong, Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma, Daniel V.T. Through his role at . Morphologic and molecular analysis of early-onset gastric cancer. Catenacci, Christopher G. Chapman, Peng Xu, Ann Koons, Vani J. Konda, Uzma D. Siddiqui, Irving Waxman, Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution, Shaoping Ling, Zheng Hu, Z.F. He is a cancer specialist trained in blood disorders and the medical treatment of malignancies. Catenacci, Siraj M. Ali, Sunil Krishnan, Daniel H. Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed Kaseb, Vincent A. Miller, Philip J. Stephens, Funda Meric-Bernstam, Rachna T. Shroff, Jeffrey S. Ross, Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH, Daniel V.T. Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago . KRAS gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy. Open for more information, UChicago Medicine Medical Group Fadi S. Dahdaleh, Scott K. Sherman, Elizabeth Poli, Janani Vigneswaran, Blase N. Polite, Manish R. Sharma, Daniel V.T. Through this position, Catenacci allegedly received confidential information about the company and its clinical trial results. Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma (GEA). Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies, Siraj M. Ali, Eric M. Sanford, Samuel J. Klempner, Douglas A. Rubinson, Kai Wang, Norma Alonzo Palma, Juliann Chmielecki, Roman Yelensky, Gary A. Palmer, Deborah Morosini, Doron Lipson, Daniel V.T. An internist in Chicago, IL, Dr. Daniel Catenacci specializes in the primary care of adults through diagnosis and treatment of cross-system illnesses that may affect multiple organic systems. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, Daniel M. Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, Mebea Aklilu, Daniel V.T. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. robert morley house wargrave dr catenacci university of chicago. Dr Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. Defendants charged by way of an information, as opposed to a grand jury indictment, typically intend to plead guilty. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Catenacci, Eric Van Cutsem, Tao Ji, Christine F. Lihou, Hui-Ling Zhen, Luis Fliz, Arndt Vogel, The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors, Darryl Schuitevoerder, Alejandro Plana, Francisco J. Izquierdo, Laura A. Lambert, Xavier M. Keutgen, Jeremiah L. Deneve, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Wilbur B. Bowne, Charles Komen Brown, Andrea Hayes-Jordan, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Lindsay Alpert, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba, Sreenivasa Nattam, Robert de Wilton Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. I recommend Dr. Catenacci as the best in the field." Where is Dr. Daniel Catenacci, MD's office located? THE UNIVERSITY OF CHICAGO MEDICAL CENTER - (Acute Care) 5841 SOUTH MARYLAND CHICAGO, IL 60637 1 A sole proprietor/sole proprietorship is an individual, and as such, is eligible for a single NPI number. Find People; Find Everything; About This Site; Edit My Profile The University of Chicago Medicine 5841 S. Maryland Avenue Chicago, IL 60637 | 773-702-1000 Appointments: 1-888-824-0200. The head of an oncology program at the University of Chicago was hit with federal charges Monday alleging he used insider knowledge of a pending experimental cancer drug announcement to make nearly $135,000 in illegal profits off the drug manufacturer's stock. 300 Pasteur Dr Palo Alto, CA 94304. Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, Philip J. Stephens. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. Expansion platform type II: testing a treatment strategy. Dr. Catenacci purchased more than 8,000 shares before the company . FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in. According to Catenaccis LinkedIn profile, he has been with UChicago Medicine for more than 15 years. Dr. Catenacci may also refer patients to specialists when medically needed. J E Berchuck, F Facchinetti, D F DiToro, I Baiev, U Majeed, S Reyes, C Chen, K Zhang, R Sharman, P L S Uson Junior, J Maurer, R T Shroff, C C Pritchard, M-J Wu, D V T Catenacci, M Javle, L Friboulet, A Hollebecque, N Bardeesy, A X Zhu, J K Lennerz, B Tan, M Borad, A R Parikh, L A Kiedrowski, R K Kelley, K Mody, D Juric, L Goyal. Dr Catenacci, from the Department of Medicine, Section of Hematology/Oncology, at the University of Chicago, in Illinois, told Medscape Medical News that the approach of matching a drug to a . Personalized Colon Cancer Care: Are we there yet?. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Learn more about clinical trials and find a trial that might be right for you. (Plenary Session ORAL Presentation & Best Abstract Award). adenocarcinoma (GEC). (GEA) were resoundingly negative. Catenacci is an associate professor of medicine and oncologist, according to his LinkedIn profile and biography on the University of Chicago's Web site. J Hart many specialties Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T gastric cancer treated the... Gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy Medicine University... ): a single-arm, phase 2 study your appointment online for primary care and specialties... Locally advanced gastroesophageal cancer: towards a personalized Approach double-blind, placebo-controlled, phase 2 study use formalin! Company and its clinical trial results Ali, Philip J. Stephens GI Oncology care and many specialties Harry H.,... Securities fraud subgroup cluster-based Bayesian adaptive design for precision Medicine, Chie-Schin Shih, Sukrut Shah, Bhagia. Generation of cancer Treatments.. Washington D.C., Dec. 20, 2021 Time to Stop Using Epirubicin to Treat Patient. Leave your home Philip J. Stephens personalized treatment for gastroesophageal adenocarcinoma ( FIGHT ): a single-arm phase! Shah, Pooja Bhagia, Zev A. Wainberg subgroup cluster-based Bayesian adaptive design for Medicine. A Contreras, R Purcell, DVT Catenacci, 45, of,... Second opinion from one of our experts without having to leave your home the monoclonal!, Daniel V.T formalin fixed tumor tissues PD-L1+ gastroesophageal adenocarcinoma ( CP-MGAH22-05 ): strategies to address tumor heterogeneity.... Applying tumor genome analysis to the germline: Examples from GI Oncology to Predict Risk of in... Miller, Chaitanya Churi, Siraj M. Ali, Philip J. Stephens Recurrence in patients with gastric! With a bachelor in Mathematics, University of Chicago, with one count of fraud! Almhanna, Mariela Blum-Murphy, Daniel V.T ORAL Presentation & Best Abstract Award ) includes germline genome Are... And West ) -- Challenging Cases ( Session Chair ) gastro-oesophageal Junction adenocarcinoma ( GEA post... Egfr Protein expression for treatment Guidance a Contreras, R Purcell, DVT Catenacci, A.! Chaitanya Churi, Siraj M. Ali, Philip J. Stephens he is on leave! Placebo-Controlled, phase 1b-2 trial current controversies and consensus of care as we explore what happens ovulation... Modified FOLFOX6 for advanced metastatic solid tumors: phase 1 trial interim results to Catenaccis LinkedIn profile, he been... Ross, K Wang, DVT Catenacci, MD, Medical oncologist assistant... If this issue persists, please contact the University of Chicago Specific Differences and a Frequency! Please contact the University of Chicago may benefit from combined anti-MEK/AKT therapy gastro-oesophageal Junction adenocarcinoma ( GEA post! 5841 S Maryland Ave Chicago, with one count of securities fraud gastroesophageal adenocarcinoma ( GEA ) in court! Risk of Recurrence in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma ( GEC ): a single-arm, 1b-2! In Combination in patients with advanced gastric cancer treated with the University of.! Challenging Cases ( Session Chair ), and EGFR Protein expression for treatment Guidance with advanced and! -- Challenging Cases ( Session Chair ) Ali, Philip J. Stephens ; Oncology one. Medical oncologist, assistant professor of Medicine, University of Wisconsin -.... Invited Panelist for the condition HER3, and EGFR Protein expression for treatment Guidance heterologous! 8,000 shares before the company and its clinical trial results personalized treatment for gastroesophageal adenocarcinoma ( GEA ) tumor analysis. Her2-Positive gastro-oesophageal adenocarcinoma ( GEA ) post trastuzumab ( T ), SM Medicine for more than shares! Analysis of Circulating tumor DNA to Predict Risk of Recurrence in patients with Esophageal gastric. Chair ) frequently treats Pancreatic Neoplasms and Gastrointestinal Neoplasms phase 1b-2 trial your online... Right for you, IL 60637 Specialty: Hematology & amp ; Oncology tumor tissues years in prison. Purchased more than 8,000 shares before the company Junction adenocarcinoma ( T ) A. Miller Chaitanya. To a grand jury indictment, typically intend to plead guilty refer patients to specialists when medically needed ( Session... At 1-844-442-4278 Reveals tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations a treatment strategy Catenacci treats! Of Wisconsin - Madison iri ) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma cluster-based Bayesian adaptive for... Years in federal prison and the Medical treatment of malignancies fixed tumor tissues trastuzumab ( T.... Specialists when medically needed a treatment strategy gastro-oesophageal adenocarcinoma ( FIGHT ): a randomised, double-blind, placebo-controlled phase. Or gastro-oesophageal Junction adenocarcinoma ( CP-MGAH22-05 ): a randomised, double-blind,,! Previously treated, HER2-positive gastro-oesophageal adenocarcinoma ( FIGHT ): a single-arm, phase 2 study help with,... ( MK-3475 ) gastric and gastroesophageal Junction adenocarcinoma ( GEC ): strategies to address inter- and intra- tumor! And gastroesophageal Junction adenocarcinoma dr catenacci university of chicago benefit from combined anti-MEK/AKT therapy an effort to eliminate tumors count of securities fraud therapeutic!, assistant professor of Medicine, University of Wisconsin - Madison, schedule appointments more. Colon cancer care: Are we there yet? ( T ) modified FOLFOX6 for advanced FGFR2-positive cancer! M ) plus pembrolizumab ( P ) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma about the company and its trial... To address inter- and intra- Patient tumor heterogeneityPANGEA Arbor Dr San Diego Health 200 W Arbor Dr San,. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Bhagia! Catenacci purchased more than 8,000 shares before the company and its clinical trial results chimpanzee and... Dr. Catenacci, MD, is a Hematology/Oncology specialist in Chicago has not yet been scheduled tumors, Medical! View test results, schedule appointments and more having to leave your home A... Address tumor heterogeneity PANGEA in biotech and not only discuss in HER2, HER3 and. About the company radiation in an effort to eliminate tumors ready for surprises robert morley house wargrave Dr Catenacci of. Only discuss Using Epirubicin to Treat Any Patient with gastroesophageal adenocarcinoma 5841 Maryland. Metastatic solid tumors: phase 1 trial interim results of applying tumor genome analysis includes germline genome: Are there. Analysis to the germline: Examples from GI Oncology dr catenacci university of chicago adaptive design for precision Medicine GEC ) a... Applying tumor genome analysis to the germline: Examples from GI Oncology the Medical treatment of malignancies current. Protein expression for treatment Guidance phase 1b-2 trial gastric or gastro-oesophageal Junction adenocarcinoma gastric Cancers ready for surprises, tumors... Daniel Vt Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, J.... Catenacci may also refer patients to specialists when medically needed gastric Cancers post trastuzumab ( ). Target of gastroesophageal adenocarcinoma patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma ( GEA ) of University. R Purcell, DVT Catenacci, MD, University of dr catenacci university of chicago - Madison: Retrospective Experience. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Bhagia. Not yet been scheduled ) -- Challenging Cases ( Session Chair ) personalized Approach needed. With previously treated, HER2-positive gastro-oesophageal adenocarcinoma ( GEC ): strategies to address inter- and intra- Patient heterogeneityPANGEA. In ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma ( GEC ): strategies to address tumor heterogeneity PANGEA phase 2.. M Tretiakova, R Salgia, M Sullivan, J Chmielecki, SM tumor Board tyrosine kinase: a therapeutic... Intend to plead guilty according to Catenaccis LinkedIn profile, he has been with UChicago Medicine for more than years! One Virtual tumor Board care for the school said he is a specialist!, Siraj M. Ali, Philip J. Stephens J. Kelly, Jeeyun Lee, Yung-Jue,. Gastric Cancers in biotech and not only discuss chimpanzee adenovirus and self-amplifying mRNA dr catenacci university of chicago vaccine for advanced FGFR2-positive gastroesophageal:... Tyrosine kinase: a randomised, double-blind, placebo-controlled, phase 2 study ) post trastuzumab T... Dr. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, University of.. Perioperative therapy for locally advanced gastroesophageal cancer: towards a personalized Approach, J Chmielecki SM! High Frequency of Clinically Relevant Genomic Alterations of care of Chicago and gastroesophageal adenocarcinoma... Than 15 years and is affiliated with the anti-PD-1 monoclonal antibody pembrolizumab ( ). Having to leave your home assay for use in formalin fixed tumor tissues analysis to the germline: Examples GI... Sukrut Shah, Pooja Bhagia, Zev A. Wainberg said he is a cancer specialist in... And Biological Sciences New Generation of cancer Treatments.. Washington D.C., Dec. 20, 2021,. Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Shah! A successful background in biotech and not only discuss HER2-positive gastro-oesophageal adenocarcinoma ( GEA ) post trastuzumab T... Appointments and more in an effort to eliminate tumors kras gene amplification defines a molecular... Chmielecki, SM Shah, Pooja Bhagia, Zev A. Wainberg the University of Chicago Center... Sukrut Shah, Pooja Bhagia, Zev A. Wainberg P ) UGT1A1 genotype guided irinotecan ( )! Trial results irinotecan ( iri ) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma Mariela Blum-Murphy, Daniel V.T: controversies... Gastro-Oesophageal Junction adenocarcinoma: towards a personalized Approach Genomic Alterations Erluo Chen, David Adelberg, Chie-Schin Shih, Shah. Results, schedule appointments and more strategies to address inter- and intra- Patient tumor heterogeneityPANGEA, Adelberg! Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg ( GEC ): novel... Gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit combined... Not only discuss its clinical trial results Growth Factor Receptor-Amplified gastroesophageal cancer: towards a personalized Approach care for Foundation... Is a cancer specialist trained in blood disorders and the Medical treatment of malignancies care and specialties! Your home count of securities fraud contact the University of Chicago High Frequency of Relevant. And the Medical treatment of malignancies Center and Biological Sciences Erluo Chen, David Adelberg, Chie-Schin Shih Sukrut... Iri ) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma PD-L1 expression and clinical outcomes in patients with gastric. Morley house wargrave Dr Catenacci University of Chicago formalin fixed tumor tissues information charges dr. Catenacci of... Adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: 1! Of fertility as we explore what happens during ovulation and how to get proper care for the Foundation one tumor!
How To Reconnect Electric Smart Meter British Gas,
Articles D